Overview
Rightangled provides personalized medicine through at-home health and DNA testing paired with online prescription delivery. It offers DNA tests for wellness, fitness, and nutrition, and an online pharmacy that dispenses medications after a clinician-guided online consultation. Tests and prescriptions are delivered to patients’ doors, supported by telehealth-style consultations. The company differentiates itself by integrating genetic testing directly with prescription delivery and digital care, backed by regulatory compliance (CQC and GPhC) and partnerships (Sibie Group, Wegoss Online Pharmacy). Its goal is to make genetic information actionable in everyday medical care, using digital tools to tailor treatments to each person’s genetic makeup.
Work here?Claim your company
Simplify's Take
What believers are saying
- Companies House shows Rightangled active in July 2026 with 2025 accounts due September.
- June 2026 oral Wegovy approval expands a high-margin category Rightangled already markets.
- Rightangled's 2026 content and Medetone links show active acquisition and dispensing infrastructure.
What critics are saying
- Reuters reported October 2023 Ozempic marketing against UK guidance, proving regulatory slippage.
- Boots, Morrisons, and Superdrug can commoditize oral semaglutide pricing by summer 2026.
- If CQC or GPhC enforcement tightens, prescription revenue collapses immediately.
What makes Rightangled unique
- Rightangled blends DNA testing, clinician consultations, and prescription dispensing under one funnel.
- Sibie Group control links Rightangled with Medetone dispensing, tightening fulfillment and compliance.
- Its 2026 Wegovy-pill coverage signals early positioning in personalized obesity treatment.
Help us improve and share your feedback! Did you find this helpful?